Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1989-03

AUTHORS

Antonio C. Buzaid, David S. Alberts, Janine Eispahr, Kurt Mosley, Yei-Mei Peng, Kendra Tutsch, Collin P. Spears, Harinder S. Garewal

ABSTRACT

Dipyridamole (DP) has previously been studied both in vitro and in vivo in combination with various anti-metabolites, including methotrexate and 5-fluorouracil (5FU). We evaluated in vitro and clinically the effects of adding DP to fluorodeoxyuridine (FUDR) in colorectal cancer. Using a human colony-forming assay, we observed that 0.05 microM DP increased the cytotoxicity of FUDR by a median of 33.5-fold vs 1.5-fold for 5FU against human colon-cancer cell lines. The mechanism of the DP-enhanced antitumor activity of FUDR is not completely understood but appears to be related to a profound inhibition by DP of thymidine accumulation in and FUDR efflux from colon-cancer cell lines. On the basis of these in vitro results, 28 patients with metastatic colon cancer were entered in a clinical trial of monthly courses of 0.1 mg/kg FUDR daily for 14 days and 75 mg oral DP 5 times daily for 14 days starting on the 3rd day of continuous i.v. FUDR infusion. The pharmacokinetics of DP was studied in three patients; the results showed that 98% of total serum DP was protein-bound and that free DP levels were significantly lower than the concentrations necessary for the expected in vitro DP/FUDR modulation. Treatment was well tolerated, with only 12 patients developing mild to moderate toxicity. Of 27 evaluable patients, 4 achieved a partial response that lasted 2, 3, 5, and 6+ months. This relatively low response rate (15%), which is similar to that achieved with FUDR alone, may be explained by the low steady-state plasma concentrations of free DP achieved in our patients. Other means of DP administration, such as i.v., i.a., and i.p. injection, may be required to achieve free DP concentrations necessary for successful biochemical modulation of FUDR in patients. More... »

PAGES

124-130

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00692352

DOI

http://dx.doi.org/10.1007/bf00692352

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010055811

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2532072


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cell Line", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chromatography, High Pressure Liquid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Colorectal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dipyridamole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Screening Assays, Antitumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Synergism", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Floxuridine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Cells, Cultured", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tumor Stem Cell Assay", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Yale University", 
          "id": "https://www.grid.ac/institutes/grid.47100.32", 
          "name": [
            "Department of Internal Medicine, Section of Medical Oncology, Yale University School of Medicine, 06510, New Haven, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Buzaid", 
        "givenName": "Antonio C.", 
        "id": "sg:person.01064440442.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064440442.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Veterans Administration Hospital, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Alberts", 
        "givenName": "David S.", 
        "id": "sg:person.07371164557.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07371164557.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Veterans Administration Hospital, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Eispahr", 
        "givenName": "Janine", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Veterans Administration Hospital, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mosley", 
        "givenName": "Kurt", 
        "id": "sg:person.01042764736.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042764736.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Veterans Administration Hospital, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Peng", 
        "givenName": "Yei-Mei", 
        "id": "sg:person.013647133307.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013647133307.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "UW Carbone Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.412639.b", 
          "name": [
            "Department of Human Oncology, University of Wisconsin Clinical Cancer Center, 53792, Madison, WI, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tutsch", 
        "givenName": "Kendra", 
        "id": "sg:person.01010043374.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010043374.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Southern California", 
          "id": "https://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Comprehensive Cancer Center, University of Southern California, 90033, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Spears", 
        "givenName": "Collin P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Arizona", 
          "id": "https://www.grid.ac/institutes/grid.134563.6", 
          "name": [
            "Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA", 
            "Veterans Administration Hospital, 85724, Tucson, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Garewal", 
        "givenName": "Harinder S.", 
        "id": "sg:person.01051026777.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051026777.13"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.3322/canjclin.35.1.19", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000902314"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(87)90168-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005572855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0006-2952(87)90168-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005572855"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/jcp.1040760111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007793060"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0304-3835(75)97506-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014601964"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0378-4347(00)81398-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027637302"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm197806152982401", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049118490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.560061", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062631608"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1078304632", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079469204", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079692360", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079733268", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079996653", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080077857", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081691615", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1984.2.4.282", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1081915036"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081983013", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082208170", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1989-03", 
    "datePublishedReg": "1989-03-01", 
    "description": "Dipyridamole (DP) has previously been studied both in vitro and in vivo in combination with various anti-metabolites, including methotrexate and 5-fluorouracil (5FU). We evaluated in vitro and clinically the effects of adding DP to fluorodeoxyuridine (FUDR) in colorectal cancer. Using a human colony-forming assay, we observed that 0.05 microM DP increased the cytotoxicity of FUDR by a median of 33.5-fold vs 1.5-fold for 5FU against human colon-cancer cell lines. The mechanism of the DP-enhanced antitumor activity of FUDR is not completely understood but appears to be related to a profound inhibition by DP of thymidine accumulation in and FUDR efflux from colon-cancer cell lines. On the basis of these in vitro results, 28 patients with metastatic colon cancer were entered in a clinical trial of monthly courses of 0.1 mg/kg FUDR daily for 14 days and 75 mg oral DP 5 times daily for 14 days starting on the 3rd day of continuous i.v. FUDR infusion. The pharmacokinetics of DP was studied in three patients; the results showed that 98% of total serum DP was protein-bound and that free DP levels were significantly lower than the concentrations necessary for the expected in vitro DP/FUDR modulation. Treatment was well tolerated, with only 12 patients developing mild to moderate toxicity. Of 27 evaluable patients, 4 achieved a partial response that lasted 2, 3, 5, and 6+ months. This relatively low response rate (15%), which is similar to that achieved with FUDR alone, may be explained by the low steady-state plasma concentrations of free DP achieved in our patients. Other means of DP administration, such as i.v., i.a., and i.p. injection, may be required to achieve free DP concentrations necessary for successful biochemical modulation of FUDR in patients.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00692352", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2435385", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2438836", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2468388", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1088364", 
        "issn": [
          "0344-5704", 
          "1432-0843"
        ], 
        "name": "Cancer Chemotherapy and Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "25"
      }
    ], 
    "name": "Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients", 
    "pagination": "124-130", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00692352"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "2fe81e3f443c02651d2199e7b76e933e84bb1c9adfe2491bfbba932a08993e71"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010055811"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "7806519"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2532072"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00692352", 
      "https://app.dimensions.ai/details/publication/pub.1010055811"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:01", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000375_0000000375/records_91444_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00692352"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00692352'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00692352'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00692352'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00692352'


 

This table displays all metadata directly associated to this object as RDF triples.

227 TRIPLES      21 PREDICATES      59 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00692352 schema:about N01da8df27f2e4cf3bd6782dc9cc3a569
2 N361530a468f74d6d812f22931afa3624
3 N37296a81642d48af8039293515d00af7
4 N63e9e3dfd9b3496193cd4e6377a4510c
5 N7a61363f8ad64d44a0069900e813cde8
6 N828241f6d865474e9931ed162df74050
7 N8348e3d7bfde4ccca12c80ac1bd2ffd5
8 N9b7d28aaf0954eb98487b031a9a7f4a7
9 Nae99b3c84e344d918b64cc8d779e0900
10 Nb89233bac61b477e923a73635aab4cd9
11 Nda6f048363264fc8a79cad871797ad9b
12 Nf252fcc2db614c93b97038e1005195f5
13 Nf853dccd13f542ab8aa627a1f2dbe961
14 anzsrc-for:11
15 anzsrc-for:1112
16 schema:author N4a11864a1a31406e82026148f2f069cb
17 schema:citation https://app.dimensions.ai/details/publication/pub.1078304632
18 https://app.dimensions.ai/details/publication/pub.1079469204
19 https://app.dimensions.ai/details/publication/pub.1079692360
20 https://app.dimensions.ai/details/publication/pub.1079733268
21 https://app.dimensions.ai/details/publication/pub.1079996653
22 https://app.dimensions.ai/details/publication/pub.1080077857
23 https://app.dimensions.ai/details/publication/pub.1081691615
24 https://app.dimensions.ai/details/publication/pub.1081983013
25 https://app.dimensions.ai/details/publication/pub.1082208170
26 https://doi.org/10.1002/jcp.1040760111
27 https://doi.org/10.1016/0006-2952(87)90168-7
28 https://doi.org/10.1016/s0304-3835(75)97506-0
29 https://doi.org/10.1016/s0378-4347(00)81398-5
30 https://doi.org/10.1056/nejm197806152982401
31 https://doi.org/10.1126/science.560061
32 https://doi.org/10.1200/jco.1984.2.4.282
33 https://doi.org/10.3322/canjclin.35.1.19
34 schema:datePublished 1989-03
35 schema:datePublishedReg 1989-03-01
36 schema:description Dipyridamole (DP) has previously been studied both in vitro and in vivo in combination with various anti-metabolites, including methotrexate and 5-fluorouracil (5FU). We evaluated in vitro and clinically the effects of adding DP to fluorodeoxyuridine (FUDR) in colorectal cancer. Using a human colony-forming assay, we observed that 0.05 microM DP increased the cytotoxicity of FUDR by a median of 33.5-fold vs 1.5-fold for 5FU against human colon-cancer cell lines. The mechanism of the DP-enhanced antitumor activity of FUDR is not completely understood but appears to be related to a profound inhibition by DP of thymidine accumulation in and FUDR efflux from colon-cancer cell lines. On the basis of these in vitro results, 28 patients with metastatic colon cancer were entered in a clinical trial of monthly courses of 0.1 mg/kg FUDR daily for 14 days and 75 mg oral DP 5 times daily for 14 days starting on the 3rd day of continuous i.v. FUDR infusion. The pharmacokinetics of DP was studied in three patients; the results showed that 98% of total serum DP was protein-bound and that free DP levels were significantly lower than the concentrations necessary for the expected in vitro DP/FUDR modulation. Treatment was well tolerated, with only 12 patients developing mild to moderate toxicity. Of 27 evaluable patients, 4 achieved a partial response that lasted 2, 3, 5, and 6+ months. This relatively low response rate (15%), which is similar to that achieved with FUDR alone, may be explained by the low steady-state plasma concentrations of free DP achieved in our patients. Other means of DP administration, such as i.v., i.a., and i.p. injection, may be required to achieve free DP concentrations necessary for successful biochemical modulation of FUDR in patients.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree false
40 schema:isPartOf N5d1c2359de234d4fb9f522b14299441f
41 Nb159b38b533a421ba6705ea28901327c
42 sg:journal.1088364
43 schema:name Effect of dipyridamole on fluorodeoxyuridine cytotoxicity in vitro and in cancer patients
44 schema:pagination 124-130
45 schema:productId N35c96afea7864da284f3bcd4dfe57305
46 N609ce7574f514d0b9844dba31e817a07
47 Na90bd4527cfa4ce89a2baa848779704c
48 Naafaf1f20dc44dfc8dc26d8d1d664c3a
49 Nba9cbfa50a154eef9eada1ae42fd7513
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010055811
51 https://doi.org/10.1007/bf00692352
52 schema:sdDatePublished 2019-04-15T09:01
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher N96e6e11406344d5f9e8e8ec71867d777
55 schema:url http://link.springer.com/10.1007/BF00692352
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N01da8df27f2e4cf3bd6782dc9cc3a569 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Drug Synergism
61 rdf:type schema:DefinedTerm
62 N159d71eece174a1bad40e251865fbb85 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
63 schema:familyName Eispahr
64 schema:givenName Janine
65 rdf:type schema:Person
66 N35c96afea7864da284f3bcd4dfe57305 schema:name readcube_id
67 schema:value 2fe81e3f443c02651d2199e7b76e933e84bb1c9adfe2491bfbba932a08993e71
68 rdf:type schema:PropertyValue
69 N361530a468f74d6d812f22931afa3624 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Humans
71 rdf:type schema:DefinedTerm
72 N370f0a64a230411a9667da21edebea9f rdf:first sg:person.013647133307.72
73 rdf:rest Na1b602fac54b4cb7988ab129a3f9500f
74 N37296a81642d48af8039293515d00af7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Floxuridine
76 rdf:type schema:DefinedTerm
77 N4a11864a1a31406e82026148f2f069cb rdf:first sg:person.01064440442.40
78 rdf:rest N76a3bdd902d046b693b95bcf45627f59
79 N4bf61ed36f4d4a57b0a74e6b9e5bb5c1 rdf:first sg:person.01042764736.14
80 rdf:rest N370f0a64a230411a9667da21edebea9f
81 N5a3e55bd6e0b4b9fa789539101e5f7b1 rdf:first N159d71eece174a1bad40e251865fbb85
82 rdf:rest N4bf61ed36f4d4a57b0a74e6b9e5bb5c1
83 N5d1c2359de234d4fb9f522b14299441f schema:volumeNumber 25
84 rdf:type schema:PublicationVolume
85 N609ce7574f514d0b9844dba31e817a07 schema:name pubmed_id
86 schema:value 2532072
87 rdf:type schema:PropertyValue
88 N63e9e3dfd9b3496193cd4e6377a4510c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Drug Therapy, Combination
90 rdf:type schema:DefinedTerm
91 N76a3bdd902d046b693b95bcf45627f59 rdf:first sg:person.07371164557.05
92 rdf:rest N5a3e55bd6e0b4b9fa789539101e5f7b1
93 N7a61363f8ad64d44a0069900e813cde8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Chromatography, High Pressure Liquid
95 rdf:type schema:DefinedTerm
96 N828241f6d865474e9931ed162df74050 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Dipyridamole
98 rdf:type schema:DefinedTerm
99 N8348e3d7bfde4ccca12c80ac1bd2ffd5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Cell Line
101 rdf:type schema:DefinedTerm
102 N96e6e11406344d5f9e8e8ec71867d777 schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 N990bdb97fee14163b34863349add6768 rdf:first sg:person.01051026777.13
105 rdf:rest rdf:nil
106 N9b7d28aaf0954eb98487b031a9a7f4a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
107 schema:name Clinical Trials as Topic
108 rdf:type schema:DefinedTerm
109 Na1b602fac54b4cb7988ab129a3f9500f rdf:first sg:person.01010043374.57
110 rdf:rest Nc7c13bf9ac3f4042b11e03e53d4cdaa6
111 Na90bd4527cfa4ce89a2baa848779704c schema:name nlm_unique_id
112 schema:value 7806519
113 rdf:type schema:PropertyValue
114 Naafaf1f20dc44dfc8dc26d8d1d664c3a schema:name dimensions_id
115 schema:value pub.1010055811
116 rdf:type schema:PropertyValue
117 Nae99b3c84e344d918b64cc8d779e0900 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Tumor Stem Cell Assay
119 rdf:type schema:DefinedTerm
120 Nb159b38b533a421ba6705ea28901327c schema:issueNumber 2
121 rdf:type schema:PublicationIssue
122 Nb89233bac61b477e923a73635aab4cd9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Colorectal Neoplasms
124 rdf:type schema:DefinedTerm
125 Nba9cbfa50a154eef9eada1ae42fd7513 schema:name doi
126 schema:value 10.1007/bf00692352
127 rdf:type schema:PropertyValue
128 Nc7c13bf9ac3f4042b11e03e53d4cdaa6 rdf:first Nf272826e0494478e830edd14299cc691
129 rdf:rest N990bdb97fee14163b34863349add6768
130 Nda6f048363264fc8a79cad871797ad9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Tumor Cells, Cultured
132 rdf:type schema:DefinedTerm
133 Nf252fcc2db614c93b97038e1005195f5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Bone Marrow
135 rdf:type schema:DefinedTerm
136 Nf272826e0494478e830edd14299cc691 schema:affiliation https://www.grid.ac/institutes/grid.42505.36
137 schema:familyName Spears
138 schema:givenName Collin P.
139 rdf:type schema:Person
140 Nf853dccd13f542ab8aa627a1f2dbe961 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Drug Screening Assays, Antitumor
142 rdf:type schema:DefinedTerm
143 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
144 schema:name Medical and Health Sciences
145 rdf:type schema:DefinedTerm
146 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
147 schema:name Oncology and Carcinogenesis
148 rdf:type schema:DefinedTerm
149 sg:grant.2435385 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00692352
150 rdf:type schema:MonetaryGrant
151 sg:grant.2438836 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00692352
152 rdf:type schema:MonetaryGrant
153 sg:grant.2468388 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00692352
154 rdf:type schema:MonetaryGrant
155 sg:journal.1088364 schema:issn 0344-5704
156 1432-0843
157 schema:name Cancer Chemotherapy and Pharmacology
158 rdf:type schema:Periodical
159 sg:person.01010043374.57 schema:affiliation https://www.grid.ac/institutes/grid.412639.b
160 schema:familyName Tutsch
161 schema:givenName Kendra
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01010043374.57
163 rdf:type schema:Person
164 sg:person.01042764736.14 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
165 schema:familyName Mosley
166 schema:givenName Kurt
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01042764736.14
168 rdf:type schema:Person
169 sg:person.01051026777.13 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
170 schema:familyName Garewal
171 schema:givenName Harinder S.
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051026777.13
173 rdf:type schema:Person
174 sg:person.01064440442.40 schema:affiliation https://www.grid.ac/institutes/grid.47100.32
175 schema:familyName Buzaid
176 schema:givenName Antonio C.
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01064440442.40
178 rdf:type schema:Person
179 sg:person.013647133307.72 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
180 schema:familyName Peng
181 schema:givenName Yei-Mei
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013647133307.72
183 rdf:type schema:Person
184 sg:person.07371164557.05 schema:affiliation https://www.grid.ac/institutes/grid.134563.6
185 schema:familyName Alberts
186 schema:givenName David S.
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07371164557.05
188 rdf:type schema:Person
189 https://app.dimensions.ai/details/publication/pub.1078304632 schema:CreativeWork
190 https://app.dimensions.ai/details/publication/pub.1079469204 schema:CreativeWork
191 https://app.dimensions.ai/details/publication/pub.1079692360 schema:CreativeWork
192 https://app.dimensions.ai/details/publication/pub.1079733268 schema:CreativeWork
193 https://app.dimensions.ai/details/publication/pub.1079996653 schema:CreativeWork
194 https://app.dimensions.ai/details/publication/pub.1080077857 schema:CreativeWork
195 https://app.dimensions.ai/details/publication/pub.1081691615 schema:CreativeWork
196 https://app.dimensions.ai/details/publication/pub.1081983013 schema:CreativeWork
197 https://app.dimensions.ai/details/publication/pub.1082208170 schema:CreativeWork
198 https://doi.org/10.1002/jcp.1040760111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007793060
199 rdf:type schema:CreativeWork
200 https://doi.org/10.1016/0006-2952(87)90168-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005572855
201 rdf:type schema:CreativeWork
202 https://doi.org/10.1016/s0304-3835(75)97506-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014601964
203 rdf:type schema:CreativeWork
204 https://doi.org/10.1016/s0378-4347(00)81398-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027637302
205 rdf:type schema:CreativeWork
206 https://doi.org/10.1056/nejm197806152982401 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049118490
207 rdf:type schema:CreativeWork
208 https://doi.org/10.1126/science.560061 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062631608
209 rdf:type schema:CreativeWork
210 https://doi.org/10.1200/jco.1984.2.4.282 schema:sameAs https://app.dimensions.ai/details/publication/pub.1081915036
211 rdf:type schema:CreativeWork
212 https://doi.org/10.3322/canjclin.35.1.19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000902314
213 rdf:type schema:CreativeWork
214 https://www.grid.ac/institutes/grid.134563.6 schema:alternateName University of Arizona
215 schema:name Pharmacology Research Program, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA
216 Section of Hematology/Oncology, Department of Internal Medicine, Arizona Cancer Center, University of Arizona College of Medicine, 85724, Tucson, AZ, USA
217 Veterans Administration Hospital, 85724, Tucson, AZ, USA
218 rdf:type schema:Organization
219 https://www.grid.ac/institutes/grid.412639.b schema:alternateName UW Carbone Cancer Center
220 schema:name Department of Human Oncology, University of Wisconsin Clinical Cancer Center, 53792, Madison, WI, USA
221 rdf:type schema:Organization
222 https://www.grid.ac/institutes/grid.42505.36 schema:alternateName University of Southern California
223 schema:name Comprehensive Cancer Center, University of Southern California, 90033, Los Angeles, CA, USA
224 rdf:type schema:Organization
225 https://www.grid.ac/institutes/grid.47100.32 schema:alternateName Yale University
226 schema:name Department of Internal Medicine, Section of Medical Oncology, Yale University School of Medicine, 06510, New Haven, CT, USA
227 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...